BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 19357714)

  • 41. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
    Wang TL; Ling M; Shih IM; Pham T; Pai SI; Lu Z; Kurman RJ; Pardoll DM; Wu TC
    Gene Ther; 2000 May; 7(9):726-33. PubMed ID: 10822298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
    Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
    J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
    Kreiter S; Selmi A; Diken M; Koslowski M; Britten CM; Huber C; Türeci O; Sahin U
    Cancer Res; 2010 Nov; 70(22):9031-40. PubMed ID: 21045153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
    Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Polo JM; Slater LA; Ling M; Wu TC
    Hum Gene Ther; 2002 Mar; 13(4):553-68. PubMed ID: 11874633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.
    Cheng WF; Hung CF; Chen CA; Lee CN; Su YN; Chai CY; Boyd DA; Hsieh CY; Wu TC
    Vaccine; 2005 May; 23(29):3864-74. PubMed ID: 15893626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.
    Kim D; Hoory T; Wu TC; Hung CF
    Hum Gene Ther; 2007 Nov; 18(11):1129-39. PubMed ID: 17939748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
    Tseng CW; Hung CF; Alvarez RD; Trimble C; Huh WK; Kim D; Chuang CM; Lin CT; Tsai YC; He L; Monie A; Wu TC
    Clin Cancer Res; 2008 May; 14(10):3185-92. PubMed ID: 18483387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control.
    Lee IH; Park JB; Cheong M; Choi YS; Park D; Sin JI
    DNA Cell Biol; 2011 Dec; 30(12):975-85. PubMed ID: 21649506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
    Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
    Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe.
    Trimble C; Lin CT; Hung CF; Pai S; Juang J; He L; Gillison M; Pardoll D; Wu L; Wu TC
    Vaccine; 2003 Sep; 21(25-26):4036-42. PubMed ID: 12922140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.
    Lin CT; Tsai YC; He L; Yeh CN; Chang TC; Soong YK; Monie A; Hung CF; Lai CH
    Immunol Lett; 2007 Dec; 114(2):86-93. PubMed ID: 17976741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
    Hung CF; Calizo R; Tsai YC; He L; Wu TC
    Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency.
    Huang B; Mao CP; Peng S; Hung CF; Wu TC
    Hum Gene Ther; 2008 Aug; 19(8):763-73. PubMed ID: 18627219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.
    Kim TW; Lee JH; He L; Boyd DA; Hung CF; Wu TC
    Hum Gene Ther; 2005 Jan; 16(1):26-34. PubMed ID: 15703486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.
    Kim D; Hoory T; Monie A; Ting JP; Hung CF; Wu TC
    J Immunol; 2008 May; 180(10):7019-27. PubMed ID: 18453624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
    Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
    Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.